THE INVESTOR

메뉴열기
March 29, 2024

Ilyang’s leukemia treatment more effective than Norvatis’ Gleevec

PUBLISHED : May 29, 2017 - 15:23

UPDATED : June 02, 2017 - 18:31

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • sms

[THE INVESTOR] Korea’s Ilyang Pharmaceutical said its leukemia drug has been found to be more effective than Novartis’ Gleevec during the final clinical studies.

Ilyang’s Supect has been statistically proven to have a better therapeutic effect in more patients than Novartis‘ Gleevec for three months treatment of patients with early diagnosis of chronic myelogenous leukemia, according to the 24-month clinical follow-up study of 241 Asian patients.




The result was presented at the 58th Spring Meeting of the Korean Society of Hematology held in Seoul on May 26.

Some 86.1 percent of patients treated with Supect for three months achieved early molecular response, which is an indication that shows improved overall survival, higher than Gleevec’s 67.9 percent.

In the six months of treatment, Suspect also achieved a higher rate of early molecular response than Gleevec at 73.4 percent and 53.1 percent, respectively.

Chronic myelogenous leukemia is a myeloproliferative disorder characterized by increased proliferation of the granulocytic cell line without the loss of their capacity to differentiate. It accounts for 20 percent of all leukemias affecting adults. It is diagnosed in one to two people per 100,000 every year, mostly between the ages of 30 and 60.

Before the US Food and Drug Administration approved Gleevec, less than one in three patients with chronic myeloid leukemia survived five years past diagnosis.

The Korean drug maker said it will announce the results of the clinical follow-up study at the European Hematology Society to be held in Spain in June.

“The conference will be a place to confirm the excellent efficacy of Asia’s first leukemia drug, Supect to global medical researchers,” the company official said.

Supect was approved as a second-line treatment at the time of launch in 2012, and it was possible to prescribe only the patients who were resistant to the existing treatment.

In February last year, however, the drug has been given approval for first-line treatment, boosting its sales. Ilyang expects that the leukemia therapy will generate sales of some 7 billion won (US$6.24 million) this year.

By Park Han-na (hnpark@heraldcorp.com)

  • 페이스북
  • sms
최상단으로
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.